Contact Information: CONTACT: Elio Evangelista 919-433-0214
Medical Affairs Departments Step Up Compliance Efforts, According to Pharmaceutical Leader Cutting Edge Information
| Source: Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwire - May 8, 2008) - A recent study by leading
business intelligence firm, Cutting Edge Information, indicates that most
pharmaceutical companies have altered the structure and procedures of their
medical affairs departments due to increased regulation. According to the
study, "Medical Affairs: Delivering Strategic Value," 92% of companies
surveyed responded that recent OIG guidelines had significantly impacted
their medical affairs structure, while 8% indicated the guidelines had
caused a complete overhaul.
In efforts to remove any influence of sales on both science and science
information, many companies have chosen to put firewalls in place between
commercial organizations and medical affairs. Often, personnel of the two
departments can only communicate through specified means or through a
meeting of heads of the departments. At some companies, the two sides do
not communicate at all.
Beyond communication, many companies have also removed any possible
budgetary conflicts. Often, companies will set a dedicated budget or have
the funds flow from the clinical side of the business. This separation of
funds ensures that medical affairs is not influenced by brand or commercial
interests when disseminating information.
Yet, many companies realize the need for different units to at least be
abreast of the others' activities. This need is epitomized by the
relationship between sales representatives and medical science liaisons.
MSLs and sales reps share the same territory and both visit physicians.
Coordination of visits is vital to maximizing the efficacy of visits.
Furthermore, many MSL groups serve as scientific support for sales groups.
Sales reps often require an information source to fully understand their
product and ensure proper representation.
"The real challenge for companies is striking a middle ground," says
research team leader Elio Evangelista. "Medical affairs departments must
be able to determine their own course independent of commercial operations
when it comes to science but, in the end, the science is still developed to
be sold. So there needs to be some interaction."
"Medical Affairs: Delivering Strategic Value" was designed to explore
pharmaceutical companies' medical affairs structures, resources and
strategies. Download a free summary of the study or purchase the report
at: http://www.cuttingedgeinfo.com/pharmamedicalaffairs/PH112_Download.asp#body
.